{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011614","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.859732+00:00","generated_at":"2026-06-04T06:47:00.847698+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Imunon reports 2023 net loss $19.5M; OVATION 2 shows ~30% PFS delay, ~9 months OS improvement","bullets":["Net loss $19.5M ($2.16 per share) vs $35.9M ($5.03 per share) in 2022; operating expenses down 17%.","Cash, investments and accrued interest $15.7M at year end; expects funding into Q4 2024.","Interim OVATION 2 data: ~30% delay in disease progression or death; ~9 month OS improvement in treatment arm vs control.","Phase 1/2 trial of IMNN-001 + bevacizumab enrolling at MD Anderson and MSK.","PlaCCine COVID-19 booster IND submitted; Phase 1 proof-of-concept expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011614","json":"https://secwatch.observer/filing/0001493152-24-011614.json","markdown":"https://secwatch.observer/filing/0001493152-24-011614.md","text":"https://secwatch.observer/filing/0001493152-24-011614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315224011614/0001493152-24-011614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315224011614/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:47:00.847698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}